{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:42:52Z","timestamp":1783485772384,"version":"3.55.0"},"reference-count":144,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Delivery"],"published-print":{"date-parts":[[2026,5,4]]},"DOI":"10.1080\/17425247.2026.2635404","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T04:46:38Z","timestamp":1771562798000},"page":"919-943","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Mechanistic and translational frontiers on\n                    <i>\u201cVEGF and TKI inhibitor axitinib\u201d<\/i>\n                    : unfolding drug delivery approaches and opportunities in cancer therapy"],"prefix":"10.1080","volume":"23","author":[{"given":"Divya","family":"Sharma","sequence":"first","affiliation":[{"name":"Birla Institute of Technology and Science","place":["Pilani, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9089-579X","authenticated-orcid":false,"given":"Shiv Kumar","family":"Prajapati","sequence":"additional","affiliation":[{"name":"GLA University","place":["Mathura, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sweta","family":"Acharya","sequence":"additional","affiliation":[{"name":"Birla Institute of Technology and Science","place":["Pilani, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8131-1860","authenticated-orcid":false,"given":"Ankit","family":"Jain","sequence":"additional","affiliation":[{"name":"Birla Institute of Technology and Science","place":["Pilani, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02419-2"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.2174\/9789815080506123010004"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.2147\/ijn.s488961"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.13179.1"},{"key":"e_1_3_5_7_1","unstructured":"Pubchem. PubChem compound summary for CID 6450551. Axitinib: National Library of Medicine; 2025 [cited 2025 Oct]. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Axitinib"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-009-0126-9"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S109640"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21249724"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-17-0243"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.70043"},{"key":"e_1_3_5_13_1","unstructured":"IARC. Cancer Tomorrow. World Health Organization; 2026 [2026 Jan 16]. Available from https:\/\/gco.iarc.fr\/tomorrow\/en\/dataviz\/isotype?types=1&single_unit=50000&populations=356&group_populations=0&multiple_populations=0&years=2050"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0044-1801767"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijmr.ijmr_1821_22"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21871"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.15586\/jkcvhl.2021.154"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11237-y"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.06.005"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.05.537"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/mog2.85"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13554-012-0005-2"},{"key":"e_1_3_5_23_1","unstructured":"Axitinib. Axitinib \u2013 treatment for advanced renal cell carcinoma: ClinicalTrials. 2014 [cited 2025 Jul]. Available from: https:\/\/www.clinicaltrialsarena.com\/projects\/axitinib-carcinoma\/?cf-view"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.4137\/CMO.S10594"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0652"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-014-1612-1"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26540"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0068-3"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.115.065615"},{"key":"e_1_3_5_30_1","unstructured":"USFDA. Inlyta tablets prescribing information USFDA. 2012 [cited 2025 Jul]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/202324lbl.pdf"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2023.03.017"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jons.2017.05.003"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12149"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1039\/c4tb01442a"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2024.114506"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(13)70465-0"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2218-676X.2014.06.10"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-5157-0"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102094"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1667"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-019-2047-4"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1163967"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.2147\/ott.s100706"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.9566"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.2975"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.125"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03867-5"},{"key":"e_1_3_5_48_1","unstructured":"Clinical and humoral impact of primary tumor ablation in metastatic renal cell carcinoma treated with immunotherapy. The ITALIC-RCC randomized study [Internet]. 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06903312"},{"key":"e_1_3_5_49_1","unstructured":"Axitinib (AG-013736) as second line therapy for metastatic renal cell cancer: axis trial [Internet]. 2008. Available from: https:\/\/clinicaltrials.gov\/study\/NCT00678392"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816047"},{"key":"e_1_3_5_51_1","unstructured":"A phase III randomized open-label ative controlled multicenter study on toripalimab combined with axitinib versus sunitinib monotheraphy as a first-line treatment for unresectable or metastatic renal cell carcinoma (RCC) [Internet]. 2020. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04394975"},{"key":"e_1_3_5_52_1","unstructured":"Phase II study on Inlyta\u00ae (Axitinib) in recurrent and\/or metastatic salivary gland cancers (SGCs) of the upper aerodigestive tract [Internet]. 2016. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02857712"},{"key":"e_1_3_5_53_1","unstructured":"A phase II study of axitinib in advanced carcinoid tumors [Internet]. 2011. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01435122"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.10.024"},{"key":"e_1_3_5_55_1","unstructured":"Phase II study of axitinib (AG-013736) with evaluation of the VEGF-pathway in metastatic recurrent or primary unresectable adrenocortical cancer [Internet]. 2010. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01255137"},{"key":"e_1_3_5_56_1","unstructured":"Phase 2 study of the anti-angiogenesis agent AG-013736 in patients with metastatic thyroid cancer who are refractory to or not suitable candidates for 131 I treatment [Internet]. 2004. Available from: https:\/\/clinicaltrials.gov\/study\/NCT00094055"},{"key":"e_1_3_5_57_1","unstructured":"Phase II study of axitinib (AG-013736) with evaluation of the VEGF-pathway in metastatic recurrent or primary unresectable pheochromocytoma\/paraganglioma [Internet]. 2019. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03839498"},{"key":"e_1_3_5_58_1","unstructured":"Phase 2 study of the anti-angiogenesis agent AG-013736 in patients with metastatic melanoma [Internet]. 2004. Available from: https:\/\/clinicaltrials.gov\/study\/NCT00094107"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-017-2629-z"},{"issue":"11","key":"e_1_3_5_60_1","first-page":"1151","article-title":"Immunopotentiating effects of Azadirachta indica (Neem) dry leaves powder in broilers, naturally infected with IBD virus","volume":"36","author":"Sadekar R","year":"1998","unstructured":"Sadekar R, Kolte A, Barmase B, et al. Immunopotentiating effects of Azadirachta indica (Neem) dry leaves powder in broilers, naturally infected with IBD virus. Indian J Exp Biol. 1998;36(11):1151\u20131153.","journal-title":"Indian J Exp Biol"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa222.612"},{"key":"e_1_3_5_62_1","unstructured":"A clinicopathological phase II study of axitinib in patients with advanced angiosarcoma and other soft tissue sarcomas [Internet]. 2010. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01140737"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30153-6"},{"key":"e_1_3_5_64_1","unstructured":"Phase I clinical trials investigating the potential efficacy of axitinib in patients with a BRCA 1\/2 mutations independent of HER2 expression with progression after previous treatment [Internet]. 2023. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05904730"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.18203\/2319-2003.ijbcp20170543"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2014.225"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.113.051193"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-015-0214-x"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2016-000875.136"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2020.587012"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26073102"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1089\/adt.2019.920"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medidd.2022.100134"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0939-6411(00)00087-4"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2009.08.004"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01849-0"},{"key":"e_1_3_5_77_1","unstructured":"ICH Q1A (R2). ICH guideline Q1A (R2) stability testing of new drug substances and products. Q1A; 2003 [2024 Feb 21]. Available from: https:\/\/database.ich.org\/sites\/default\/files\/Q1A%28R2%29%20Guideline.pdf"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1201\/9781003043164-2"},{"key":"e_1_3_5_79_1","unstructured":"ICH(Q9). Quality risk management. 2005 [2024 Jun 6]. Available from: https:\/\/database.ich.org\/sites\/default\/files\/Q9_Guideline.pdf"},{"key":"e_1_3_5_80_1","unstructured":"ICHQ8(R2). Pharmaceutical development. 2009 [cited 2024 Jun 6]. Available from: https:\/\/database.ich.org\/sites\/default\/files\/Q8_R2_Guideline.pdf"},{"key":"e_1_3_5_81_1","unstructured":"ICH. Pharmaceutical quality system Q10. 2008 [2024 Oct 5]. Available from: https:\/\/database.ich.org\/sites\/default\/files\/Q10%20Guideline.pdf"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2024.106107"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14040883"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15020514"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2014.00069"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seminoncol.2025.152429"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12645-025-00321-6"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.3390\/life14060672"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2022.103891"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41597-023-02812-w"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2016.1218462"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S488545"},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.1201\/9781003517870-4"},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.1039\/D3NR03495J"},{"key":"e_1_3_5_95_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S480639"},{"key":"e_1_3_5_96_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-023-02696-4"},{"key":"e_1_3_5_97_1","doi-asserted-by":"publisher","DOI":"10.1080\/10667857.2025.2495346"},{"key":"e_1_3_5_98_1","doi-asserted-by":"publisher","DOI":"10.1002\/pat.70198"},{"key":"e_1_3_5_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2023.105156"},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.3390\/gels10060404"},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules30143044"},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.3c02783"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2023.124338"},{"key":"e_1_3_5_104_1","doi-asserted-by":"publisher","DOI":"10.7150\/thno.38069"},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12020417"},{"key":"e_1_3_5_106_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14081727"},{"key":"e_1_3_5_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2021.102725"},{"key":"e_1_3_5_108_1","doi-asserted-by":"publisher","DOI":"10.7150\/thno.19987"},{"key":"e_1_3_5_109_1","doi-asserted-by":"publisher","DOI":"10.1039\/C0NR00156B"},{"key":"e_1_3_5_110_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076615"},{"key":"e_1_3_5_111_1","volume-title":"Theranostic liposome for brain tumor diagnosis and treatment. Brain tumor targeting drug delivery systems: advanced nanoscience for theranostics applications","author":"Kesharwani P","year":"2023","unstructured":"Kesharwani P, Kumar Prajapati S, Kapoor D, et al. Theranostic liposome for brain tumor diagnosis and treatment. Brain tumor targeting drug delivery systems: advanced nanoscience for theranostics applications. Singapore: Bentham Science Publishers; 2023."},{"key":"e_1_3_5_112_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-024-02664-5"},{"key":"e_1_3_5_113_1","doi-asserted-by":"publisher","DOI":"10.1039\/d5tb01481f"},{"key":"e_1_3_5_114_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14122706"},{"key":"e_1_3_5_115_1","doi-asserted-by":"publisher","DOI":"10.22270\/jddt.v11i1.4677"},{"key":"e_1_3_5_116_1","unstructured":"Kim J-O Yong C-S Choi J-Y inventor. Drug delivery system comprising axitinib and preparing method thereof. South korea: 2015."},{"key":"e_1_3_5_117_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-025-03170-y"},{"key":"e_1_3_5_118_1","doi-asserted-by":"publisher","DOI":"10.35629\/4494-1002318321"},{"key":"e_1_3_5_119_1","unstructured":"Zhou Q Huang J Wang L et al. inventor. Self-microemulsion formulations of axitinib. China: 2020. [2020 Feb 12]."},{"key":"e_1_3_5_120_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16020223"},{"key":"e_1_3_5_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2023.100837"},{"key":"e_1_3_5_122_1","doi-asserted-by":"publisher","DOI":"10.31351\/vol33iss3pp115-127"},{"key":"e_1_3_5_123_1","doi-asserted-by":"publisher","DOI":"10.31351\/vol34iss3pp65-77"},{"key":"e_1_3_5_124_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2025.110364"},{"key":"e_1_3_5_125_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16060697"},{"key":"e_1_3_5_126_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0325511"},{"key":"e_1_3_5_127_1","doi-asserted-by":"publisher","DOI":"10.3390\/nano14151305"},{"key":"e_1_3_5_128_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrev.8b00593"},{"key":"e_1_3_5_129_1","doi-asserted-by":"publisher","DOI":"10.1109\/TNB.2025.3639054"},{"key":"e_1_3_5_130_1","doi-asserted-by":"publisher","DOI":"10.3390\/gels11060426"},{"key":"e_1_3_5_131_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2021.102914"},{"key":"e_1_3_5_132_1","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2023.1140436"},{"key":"e_1_3_5_133_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2023.05.018"},{"key":"e_1_3_5_134_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.2010.01139.x"},{"key":"e_1_3_5_135_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2020.101643"},{"key":"e_1_3_5_136_1","unstructured":"Zhai L Liu J Yu J inventor. Axitinib cyclodextrin inclusion compound. China: 2019."},{"key":"e_1_3_5_137_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.comptc.2025.115091"},{"key":"e_1_3_5_138_1","doi-asserted-by":"publisher","DOI":"10.3390\/polym14050936"},{"key":"e_1_3_5_139_1","doi-asserted-by":"publisher","DOI":"10.1021\/acssuschemeng.0c06044"},{"key":"e_1_3_5_140_1","doi-asserted-by":"publisher","DOI":"10.1039\/d3bm00861d"},{"key":"e_1_3_5_141_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2016.04.060"},{"key":"e_1_3_5_142_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.cgd.5c01232"},{"key":"e_1_3_5_143_1","doi-asserted-by":"publisher","DOI":"10.1039\/d3na00397c"},{"key":"e_1_3_5_144_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2023.2218084"},{"key":"e_1_3_5_145_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12645-024-00250-w"},{"key":"e_1_3_5_146_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2016.05.012"}],"container-title":["Expert Opinion on Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425247.2026.2635404","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T13:57:44Z","timestamp":1777903064000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425247.2026.2635404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":144,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,4]]}},"alternative-id":["10.1080\/17425247.2026.2635404"],"URL":"https:\/\/doi.org\/10.1080\/17425247.2026.2635404","relation":{},"ISSN":["1742-5247","1744-7593"],"issn-type":[{"value":"1742-5247","type":"print"},{"value":"1744-7593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-12-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}